RAS G12 Targeting

Interviews and expert commentary tagged “RAS G12 Targeting” — the latest oncology research and clinical practice from the Audio Journal of Oncology.

Eileen M O'Reilly MD; ASCO 2026: RAS G12 Targeting Drug Daraxonrasib Doubles Survival with Pancreas Cancer in Phase 3 RASolute 302 Study
Audio Journal of Oncology

Eileen M O'Reilly MD; ASCO 2026: RAS G12 Targeting Drug Daraxonrasib Doubles Survival with Pancreas Cancer in Phase 3 RASolute 302 Study

Standing ovation at ASCO for RASolute 302 Study

2 June 2026
13:29
← Browse all episodes